OI Therapy Raised BMD, Not Fracture Benefit - Takeaways - MDSpire

OI Therapy Raised BMD, Not Fracture Benefit

Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.

  • By

  • Andrea Surnit

  • June 5, 2026

  • 7 min

Share

  • 1

    The TOPaZ trial found no significant reduction in fractures for adults with osteogenesis imperfecta treated with teriparatide and zoledronic acid.

  • 2

    Bone mineral density increased in the intervention group, but this did not correlate with a decrease in imaging-confirmed fractures.

  • 3

    Adherence to treatment was high in the intervention group at 98.3%, compared to 44.5% in the standard-care group.

  • 4

    Secondary analyses showed no statistically significant fracture benefit from teriparatide followed by zoledronic acid.

  • 5

    The study's limitations included fewer primary outcome fractures than expected, affecting the ability to detect treatment effects.

Original Source(s)

OI Therapy Raised BMD, Not Fracture Benefit

  • by Andrea Surnit

  • June 5, 2026

Related Content

Development and validation of a predictive nomogram for cage migration after posterior lumbar interbody fusion: a retrospective study of 517 patients

Cable-Plate augmentation improves the therapeutic effect of intramedullary nailing for AO/OTA type A2.3 intertrochanteric fractures with large coronal fragments: a double-center retrospective study

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.